Company / R&D Expense
Protalix BioTherapeutics, Inc. R&D Expense History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$17.1M
FY2025
5-year range
$17.1M / $44.6M
FY2021-FY2025
Trend
-41.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 4 consecutive years, from $45M in FY2021 to $17M in FY2025.
Based on SEC 10-K filings.
$17M in FY2025 with a 10-year CAGR of -5.2%.
Declined from $30M to $17M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -23.5%
- 5-Year CAGR
- -12.5%
- 10-Year CAGR
- -5.2%
Key checks
Key Insights
- Protalix BioTherapeutics, Inc.'s r&d expense has declined for 4 consecutive years.
- 5-year CAGR of -12.5%, indicating a declining trend.
- In FY2025, r&d expense decreased 41.8% year-over-year.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.1M | -41.8% |
| FY2024 | $29.3M | -1.3% |
| FY2023 | $29.7M | -22.1% |
| FY2022 | $38.2M | -14.5% |
| FY2021 | $44.6M | +33.9% |
| FY2020 | $33.3M | +3.6% |
| FY2019 | $32.2M | +29.3% |
| FY2017 | $24.9M | -9.0% |
| FY2016 | $27.4M | -6.4% |
| FY2015 | $29.2M | -20.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026